Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00144794 · ClinicalTrials.gov registry record
Mucopolysaccharidosis I (MPS I) Registry
A clinical trial, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- 1,406
- Enrollment target
NCT00144794: Completed study, sponsored by Genzyme, a Sanofi Company.
NCT00144794 is a clinical trial that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 1,406 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00144794 has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- 1,406 participants
- Enrollment target
Study Summary
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities. The objectives of the Registry are: * To evaluate the long-term effectiveness and safety of Aldurazyme® (laronidase) * To characterize and describe the MPS I population as a whole, including the variability, progression, and natural history of MPS I * To help the MPS I medical community with the development of recommendations for monitoring patients and reports on patient outcomes to optimize patient care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,406 participants |
| Start Date | 2003-11-20 |
| Est. Completion | 2024-12-31 |
What the finished NCT00144794 record still lists
NCT00144794 is an observational study that tracks outcomes without assigning an intervention. Its 1,406 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00144794 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00144794 about?
NCT00144794 is a clinical study titled "Mucopolysaccharidosis I (MPS I) Registry". The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses ...
What is the current status of trial NCT00144794?
This trial is currently completed. The enrollment target is 1,406 participants. The study started on 2003-11-20. Estimated completion is 2024-12-31.
Who is sponsoring clinical trial NCT00144794?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05992935 · 1,405 participants · Phase 1
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
- NCT05444582 · 1,404 participants · Phase 4
Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start
- NCT05890404 · 1,410 participants · NA
SGM Evidenced-Based Mental Healthcare Implementation
- NCT07042451 · 1,410 participants · NA
An Evaluation of the Pink Cloud Application in Post- Treatment Substance Use Disorder Support
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI